Primary infection with the Epstein-Barr virus and risk of multiple sclerosis

Annals of Neurology

Volumn 67, Issue 6, 2010, Pages 824-830

  Levin, Lynn I ^a   Munger, Kassandra L ^b   O'Reilly, Eilis J ^b   Falk, Kerstin I ^c,d   Ascherio, Alberto ^b,e  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTIBODY TITER; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIMARY INFECTION; PRIORITY JOURNAL; RISK ASSESSMENT; SEROCONVERSION; VIRUS INFECTION;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CASE-CONTROL STUDIES; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HUMANS; MALE; MILITARY PERSONNEL; MULTIPLE SCLEROSIS; RISK FACTORS; VIRAL PROTEINS; YOUNG ADULT;

EID: 77952921203     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21978     Document Type: Article

References (24)

1. Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 2006;59:499-503. (Pubitemid 43358070)
2. Nielsen TR, Rostgaard K, Nielsen NM, et al. Multiple sclerosis after infectious mononucleosis. Arch Neurol 2007;64:72-75.
3. Ascherio A, Munger KL, Lennette ET, et al. Epstein-barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001;286:3083-3088.
4. Sundstrom P, Juto P, Wadell G, et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 2004;62:2277-2282. (Pubitemid 38787787)
5. Levin LI, Munger KL, Rubertone MV, et al. Temporal relationship between elevation of Epstein Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005;293:2496-2500.
6. DeLorenze GN, Munger KL, Lennette E, et al. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch Neurol 2006;63:839-844. (Pubitemid 43882291)
7. Ascherio A, Munch M. Epstein-Barr virus and multiple sclerosis. Epidemiology 2000;11:220-224.
8. Alotaibi S, Kennedy J, Tellier R, et al. Epstein-Barr virus in pediatric multiple sclerosis. JAMA 2004;291:1875-1879. (Pubitemid 38509501)
9. Pohl D, Krone B, Rostasy K, et al. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology 2006;67:2063-2065. (Pubitemid 44967394)
10. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: The role of infection. Ann Neurol 2007;61:288-299.
11. Rubertone MV, Brundage JF. The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance. Am J Public Health 2002;92:1900-1904.
12. Munger KL, Levin LI, Hollis BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296:2832-2838.
13. Rothman K, Greenland S. Modern epidemiology. 2nd ed. Philadelphia, PA: Lippincott-Raven Publishers, 1998.
14. Henle W, Henle GE, Horwitz CA. Epstein-Barr virus specific diagnostic tests in infectious mononucleosis. Hum Pathol 1974;5:551-565.
15. Linde A, Andersson J, Lundgren G, Wahren B. Subclass reactivity to Epstein-Barr virus capsid antigen in primary and reactivated EBV infections. J Med Virol 1987;21:109-121.
16. Lennette ET, Rymo L, Yadav M, et al. Disease-related differences in antibody patterns against EBV-encoded nuclear antigens EBNA 1, EBNA 2 and EBNA 6. Eur J Cancer 1993;29A:1584-1589.
17. Lennette ET, Lennette D. Immune adherence hemagglutination. In: Specter S, Hodinka R, Young S, eds. Clinical virology manual. Washington, DC: ASM Press, 2000:140-145.
18. Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howley PM, Griffin DE, et al, eds. Fields virology. Vol 2. 5th ed. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2007:2655-2700.
19. Niederman JC, Evans AS. Epstein-Barr virus. In: Evans AS, Kaslow RA, eds. Viral infections of humans: epidemiology and control. 4th ed. New York, NY: Plenum Medical Book Company, 1997:253-283.
20. Crawford DH, Macsween KF, Higgins CD, et al. A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis 2006;43:276-282.
21. Evans AS, Niederman JC, McCollum RW. Seroepidemiologic studies of infectious mononucleosis with EB virus. N Engl J Med 1968;279:1121-1127.
22. Sawyer RN, Evans AS, Niederman JC, McCollum RW. Prospective studies of a group of Yale University freshmen. I. Occurrence of infectious mononucleosis. J Infect Dis 1971;123:263-270.
23. Lebrun C, Bensa C, Debouverie M, et al. Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile. J Neurol Neurosurg Psychiatry 2008;79:195-198. (Pubitemid 351236555)
24. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol 2007;61:504-513.